Quotes 5-day view Delayed London Stock Exchange
01/18/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
7662(c)
7722(c)
7645(c)
7650(c)
7777(c)
Last
1 167 671
2 530 444
1 950 270
2 126 404
2 462 698
Volume
+0.92% +0.78% -1.00% +0.07% +1.66% Change
Sales 2020
26 404 M - -
Net income 2020
2 955 M - -
Net Debt 2020
13 238 M - -
P/E ratio 2020
42,5x
Yield 2020
2,65%
Sales 2021
30 409 M - -
Net income 2021
4 577 M - -
Net Debt 2021
11 668 M - -
P/E ratio 2021
29,8x
Yield 2021
2,69%
Capitalization
140 B 139 B -
EV / Sales 2020
5,79x
EV / Sales 2021
4,98x
Nbr of Employees
70 600
Free-Float
95,7%
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows:
- oncology (36.8%);
- respiratory diseases (22.9%);
- cardiovascular, renal and metabolic diseases (18.6%);
- other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases.
Net sales are distributed geographically as follows: the United...
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
All news about ASTRAZENECA PLC
News in other languages on ASTRAZENECA PLC
Analyst Recommendations on ASTRAZENECA PLC
ASTRAZENECA PLC - 01/18
The underlying trend is in force again
BUY
AstraZeneca : Foreigners net sellers of Asian equities in 2020, despite fourth-quarter turnaround
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ASTRAZENECA PLC
Short Term Mid-Term Long Term Trends Neutral Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
25
Average target price
126,47 $
Last Close Price
106,39 $
Spread / Highest target
46,7%
Spread / Average Target
18,9%
Spread / Lowest Target
-15,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
